Please try another search
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Name | Age | Since | Title |
---|---|---|---|
David Drew | - | - | Member of Scientific Advisory Board |
Gunnar Von Heijne | - | - | Member of Scientific Advisory Board |
Joen Luirink | - | - | Member of Scientific Advisory Board |
Karin Wingstrand | 64 | 2015 | Independent Director |
Anders Lennart Tullgren | 60 | 2018 | Independent Chairman of the Board |
Peter Edman | 67 | 2015 | Independent Director |
Eva Nilsagard | 57 | 2019 | Independent Director |
Björn Olof Nilsson | 65 | - | Member of Scientific Advisory Board |
Samuel Wagner | - | 2008 | Co-Founder & Member of Scientific Advisory Board |
Mats Thoren | 51 | 2020 | Independent Director |
Ivan Cohen-Tanugi | 61 | 2019 | Independent Director |
Kirsti Gjellan | - | 2022 | Independent Director |
Kirsti Gjellan | 60 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review